StemEdit Gene Edited iPSCs

Brand: StemEdit by Stemgent® (REPROCELL®)

High-quality HLA knockout iPSC lines were developed using our state-of-the-art genome editing technology, utilizing an AI-enhanced nuclease system. This editing system is also well-suited for clinical gene-editing projects.

NOTE: These iPSC cell lines are developed and supplied for Research Use Only (RUO). They are not intended for clinical or therapeutic applications. However, this clone has a clinical-grade counterpart available that is suitable for clinical gene editing and downstream clinical development. Contact Us for more information.

See also:

StemEdit OC-1 Protein — Our license-free AI-designed protein for robust gene editing
StemEdit Clinical Gene Editing Service — Our license-free editing services
Clinical Stem Cell Services — Clinical-grade iPSC solutions and lines
StemRNA™ Induced Pluripotent Stem Cells (iPSCs) — Research-grade iPSC collection

NEW OFFER: the clinical parental control iPSC line—used to develop our StemEdit hypoimmune iPSC lines—is now available in an affordable bundle with these gene-edited clones.

Interested? Reach out directly at info-us@reprocellusa.com for details.

Products:

StemEdit hiPSC CIITA KO RPC-LLF-34-F3

Brand: StemEdit

RCRP051

Human iPS Cells established from fibroblasts, reprogrammed with REPROCELL's StemRNA Reprogramming technology, with knockout in the CIITA (HLA Class II) genes.

StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3

Brand: StemEdit

RCRP052

Human iPSCs established from fibroblasts, reprogrammed with REPROCELL's Clinical StemRNA Reprogramming technology, with double knockout in the B2M (HLA Class I) and CIITA (HLA Class II) genes.

StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3

StemEdit hiPSC B2M KO

Brand: StemEdit

RCRP053

Human iPSCs established from fibroblasts, reprogrammed with REPROCELL's Clinical StemRNA Reprogramming technology, with a knockout of both alleles of the B2M (HLA Class I) gene.